Morteza Ghandadi

932 total citations
30 papers, 763 citations indexed

About

Morteza Ghandadi is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Morteza Ghandadi has authored 30 papers receiving a total of 763 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Organic Chemistry. Recurrent topics in Morteza Ghandadi's work include Synthesis and biological activity (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Computational Drug Discovery Methods (4 papers). Morteza Ghandadi is often cited by papers focused on Synthesis and biological activity (6 papers), Drug Transport and Resistance Mechanisms (4 papers) and Computational Drug Discovery Methods (4 papers). Morteza Ghandadi collaborates with scholars based in Iran, United States and Italy. Morteza Ghandadi's co-authors include Amirhossein Sahebkar, Mehrdad Iranshahi, Fatemeh Mosaffa, Bahman Khameneh, Milad Iranshahy, Khalil Abnous, Bibi Sedigheh Fazly Bazzaz, Javad Behravan, Afshin Zarghi and Razieh Ghodsi and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Journal of Medicinal Chemistry and Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.

In The Last Decade

Morteza Ghandadi

28 papers receiving 754 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Morteza Ghandadi Iran 14 332 189 123 95 82 30 763
Elisa Pierpaoli Italy 20 387 1.2× 94 0.5× 52 0.4× 80 0.8× 110 1.3× 42 865
Xinqiang Song China 16 389 1.2× 70 0.4× 80 0.7× 89 0.9× 72 0.9× 41 945
Mangala Hegde India 17 374 1.1× 53 0.3× 167 1.4× 78 0.8× 91 1.1× 51 967
Yi-Shih Ma Taiwan 13 423 1.3× 57 0.3× 135 1.1× 93 1.0× 125 1.5× 14 735
Mohammad Jalili‐Nik Iran 18 338 1.0× 44 0.2× 99 0.8× 110 1.2× 107 1.3× 52 862
Panjamurthy Kuppusamy India 19 502 1.5× 161 0.9× 34 0.3× 170 1.8× 180 2.2× 38 1.2k
Khushbukhat Khan Pakistan 16 415 1.3× 52 0.3× 58 0.5× 77 0.8× 125 1.5× 65 803
J D Laskin United States 11 524 1.6× 66 0.3× 164 1.3× 102 1.1× 63 0.8× 13 1.0k
An-Cheng Huang Taiwan 17 557 1.7× 71 0.4× 59 0.5× 131 1.4× 128 1.6× 20 901
Bum‐Sang Shim South Korea 15 446 1.3× 51 0.3× 91 0.7× 107 1.1× 107 1.3× 39 926

Countries citing papers authored by Morteza Ghandadi

Since Specialization
Citations

This map shows the geographic impact of Morteza Ghandadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Morteza Ghandadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Morteza Ghandadi more than expected).

Fields of papers citing papers by Morteza Ghandadi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Morteza Ghandadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Morteza Ghandadi. The network helps show where Morteza Ghandadi may publish in the future.

Co-authorship network of co-authors of Morteza Ghandadi

This figure shows the co-authorship network connecting the top 25 collaborators of Morteza Ghandadi. A scholar is included among the top collaborators of Morteza Ghandadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Morteza Ghandadi. Morteza Ghandadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ghandadi, Morteza, et al.. (2025). An overview of isatin-derived CDK2 inhibitors in developing anticancer agents. European Journal of Medicinal Chemistry. 295. 117819–117819. 2 indexed citations
2.
Ghandadi, Morteza, Albert Dobi, & Sanjay V. Malhotra. (2024). A role for RIO kinases in the crosshair of cancer research and therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(3). 189100–189100. 2 indexed citations
3.
4.
Ghandadi, Morteza. (2023). Docking-based virtual screening and molecular dynamic studies to identify new RIOK2 inhibitors. Chemical Papers. 77(7). 3651–3661. 1 indexed citations
5.
Karami, Mohammad, et al.. (2022). Quercetin ameliorates Di (2-ethylhexyl) phthalate-induced nephrotoxicity by inhibiting NF-κB signaling pathway. Toxicology Research. 11(2). 272–285. 22 indexed citations
6.
Ghandadi, Morteza. (2022). An Immunoinformatic Strategy to Develop New Mycobacterium tuberculosis Multi-epitope Vaccine. International Journal of Peptide Research and Therapeutics. 28(3). 99–99. 13 indexed citations
7.
8.
Ghandadi, Morteza, et al.. (2019). Wnt-β-catenin Signaling Pathway, the Achilles' Heels of Cancer Multidrug Resistance. Current Pharmaceutical Design. 25(39). 4192–4207. 21 indexed citations
9.
Ghandadi, Morteza, et al.. (2017). TNF-α exerts cytotoxic effects on multidrug resistant breast cancer MCF-7/MX cells via a non-apoptotic death pathway. Cytokine. 97. 167–174. 8 indexed citations
10.
Ghandadi, Morteza & Amirhossein Sahebkar. (2016). Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance. Current Pharmaceutical Design. 22(5). 518–526. 64 indexed citations
11.
Ghandadi, Morteza & Amirhossein Sahebkar. (2016). Curcumin: An Effective Inhibitor of Interleukin-6. Current Pharmaceutical Design. 23(6). 921–931. 163 indexed citations
12.
Khameneh, Bahman, Mohammad Reza Saberi, Mohammad Hassanzadeh-Khayyat, et al.. (2016). Evaluation of physicochemical and stability properties of human growth hormone upon enzymatic PEGylation. Journal of Applied Biomedicine. 14(4). 257–264. 13 indexed citations
13.
Mosaffa, Fatemeh, et al.. (2016). Synthesis and biological evaluation of quinoline analogues of flavones as potential anticancer agents and tubulin polymerization inhibitors. European Journal of Medicinal Chemistry. 114. 14–23. 88 indexed citations
14.
Ghandadi, Morteza & Amirhossein Sahebkar. (2016). MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance. Current Pharmaceutical Design. 22(7). 933–939. 34 indexed citations
15.
Ghandadi, Morteza, Javad Behravan, Khalil Abnous, & Fatemeh Mosaffa. (2015). Reactive Oxygen Species Mediate TNF-⍺ Cytotoxic Effects in the Multidrug-Resistant Breast Cancer Cell Line MCF-7/MX. Oncology Research and Treatment. 39(1-2). 54–59. 10 indexed citations
16.
Shayanfar, Ali, et al.. (2015). Image‐Based Analysis to Predict the Activity of Tariquidar Analogs as P‐Glycoprotein Inhibitors: The Importance of External Validation. Archiv der Pharmazie. 349(2). 124–131. 5 indexed citations
17.
Kasaian, Jamal, Fatemeh Mosaffa, Javad Behravan, et al.. (2015). Reversal of P-glycoprotein-mediated multidrug resistance in MCF-7/Adr cancer cells by sesquiterpene coumarins. Fitoterapia. 103. 149–154. 62 indexed citations
18.
Khameneh, Bahman, et al.. (2014). Investigation of the antibacterial activity and efflux pump inhibitory effect of co-loaded piperine and gentamicin nanoliposomes in methicillin-resistantStaphylococcus aureus. Drug Development and Industrial Pharmacy. 41(6). 989–994. 98 indexed citations
19.
Abnous, Khalil, et al.. (2014). Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors. Bioorganic Chemistry. 57. 83–89. 38 indexed citations
20.
Ghandadi, Morteza, et al.. (2012). Quantitative structure activity relationship and docking studies on imidazole derivatives as P-glycoprotein inhibitors. Research in Pharmaceutical Sciences. 7(5). 559.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisa Pierpaoli Breakdown of academic impact, for papers by Xinqiang Song Breakdown of academic impact, for papers by Mangala Hegde Breakdown of academic impact, for papers by Yi-Shih Ma Breakdown of academic impact, for papers by Mohammad Jalili‐Nik Breakdown of academic impact, for papers by Panjamurthy Kuppusamy Breakdown of academic impact, for papers by Khushbukhat Khan Breakdown of academic impact, for papers by J D Laskin Breakdown of academic impact, for papers by An-Cheng Huang Breakdown of academic impact, for papers by Bum‐Sang Shim
Rankless by CCL
2026